{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "MK-677",
    "short_name": "MK-677",
    "aliases": [
      "ibutamoren",
      "mk677",
      "mk 677"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what MK-677 is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how MK-677 appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "title": "What it is",
          "text": "MK-677 (ibutamoren) is an investigational, oral ghrelin-receptor agonist that increases growth hormone and IGF-1 signaling. It is not approved as a general wellness compound."
        },
        {
          "title": "Why people discuss it",
          "text": "It’s commonly discussed for appetite, sleep/recovery feelings, and body-composition goals. Practical downsides frequently center on appetite/weight gain, fluid retention, and glucose tolerance."
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "sleep quality support",
        "falling asleep more easily (anecdotal)",
        "staying asleep through the night (anecdotal)",
        "circadian rhythm support",
        "next-day recovery and readiness support"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for MK-677",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": false,
    "meta": {
      "priority": "normal",
      "notes_seed": "Ibutamoren (MK-677) is a small-molecule ghrelin receptor agonist / GH secretagogue (not a peptide); investigational/controlled contexts; avoid protocols."
    },
    "topics": {
      "primary": [
        "topic_hormonal_endocrine",
        "topic_muscle_recovery",
        "topic_sleep_circadian"
      ]
    },
    "slug": "mk-677"
  },
  "canonical_name": "Mk-677",
  "interactions": {
    "drug_classes": [
      "endocrine-axis-modulation-context"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "MK-677 (ibutamoren) is an investigational oral ghrelin-receptor agonist that increases growth hormone/IGF-1 signaling. It’s often discussed for sleep, appetite, and body-composition goals, but tradeoffs commonly involve appetite/weight gain, fluid retention, and glucose tolerance concerns.",
    "benefits": [
      "Increases GH/IGF-1 signaling in studies (mechanistic effect)",
      "Often discussed for sleep quality or recovery feelings (mixed reports)",
      "Often discussed for appetite and weight gain (common effect)"
    ],
    "side_effects_common": [
      "Increased appetite / cravings",
      "Water retention or puffiness",
      "Fatigue or lethargy",
      "Numbness/tingling or carpal-tunnel-like complaints (reports vary)",
      "Vivid dreams (reports vary)"
    ],
    "side_effects_serious": [
      "Worsening blood sugar control signs (excess thirst/urination, blurry vision)",
      "Rapid swelling, shortness of breath, or chest pain",
      "Severe headaches or neurologic symptoms"
    ],
    "who_should_be_cautious": [
      "Diabetes, prediabetes, metabolic syndrome, or strong family history (glucose tolerance concern)",
      "Heart failure / edema-prone conditions",
      "Pregnant or breastfeeding individuals",
      "Adolescents (growth/endocrine setpoints; not an appropriate context)"
    ],
    "schema_version": "practical_block_v1"
  }
}
